Furthermore, CKS2 promoted the EMT‐like process through TGFβ/SMAD signaling pathway in glioma, meanwhile, inhibition of TGFβ/SMAD could reverse the malignant phenotype caused by CKS2, which implied that CKS2 may serve as a potential target for the treatment of glioma. This evidence concerns the gene CKS2 and glioma.